Abstract
Abstract
Background
Anti-Müllerian hormone (AMH) is secreted by granulosa cells in preantral follicles and small antral follicles. There is limited information about whether serum AMH levels are related to pregnancy outcomes during in vitro fertilization and embryo transfer (IVF-ET). The aim of this study was to provide a theoretical basis for improving pregnancy outcomes.
Methods
A retrospective cohort study was conducted on infertile women who were treated at the Reproductive Centre of the Affiliated Hospital of Southwest Medical University between September 2018 and September 2019. The sample included 518 participants from Southwest China. The participants were divided into 2 groups according to their AMH level. Their data were retrieved from the medical records: days and dosage of gonadotropin (Gn) (one bottle equals 75 IU), the number of oocytes obtained, the number of oocytes in metaphase II (MII) and the number of high-quality embryos. The pregnancy outcomes were followed up and divided into two groups according to whether they were pregnant or not, with statistical analysis of the parameters related to the in vitro fertilization process performed separately.
Results
Compared to a lower AMH level (AMH ≤ 1.1), a higher AMH level (AMH > 1.1) resulted in less total Gn (bottle) (P = 0.00 < 0.05) and a lower starting Gn (IU) (P = 0.00 < 0.05), while the number of oocytes obtained,MII,cleavages and high-quality embryos were higher (P = 0.00 < 0.05). The participants' pregnancy outcomes (ectopic pregnancy, miscarriage, singleton, twin, multiple births) were found to not be predictable by AMH through ROC curves (P = 0.980, 0.093, 0.447, 0.146, 0.526, and 0.868 > 0.05). For participants in the pregnancy group, although AMH was lower in the nonpregnant participants(P = 0.868 > 0.05), the difference was not statistically significant, and the correlation coefficients between the two groups suggested no differences in the IVF process, except for the starting Gn (IU) (P = 0.038 < 0.05).
Conclusion
AMH has clinical application value in predicting ovarian reserve function, providing guidance and suggestions for the specific formulation of ovulation promotion programs with assisted reproductive technology, but it cannot effectively predict the outcome of clinical pregnancy.
Funder
The southwest medical universit
Luzhou science and Technology Bureau
Publisher
Springer Science and Business Media LLC
Subject
Obstetrics and Gynecology,Reproductive Medicine
Reference26 articles.
1. Chang HM, Zhu YM, Leung PCK. Chapter 7 - Cell-cell interactions in ovarian follicles: role of TGF-β superfamily members. The Ovary (Third Edition). 2019:107–125. https://doi.org/10.1016/B978-0-12-813209-8.00007-8.
2. Zheng M, Cheng N. Anti-Müllerian hormone combined with age on ovarian reserve function based on the number of basic antral follicles Evaluation value. Fujian Med J. 2017;39:94–6.
3. Claudia M, Valentina LP, Fausta S, Scaruff P, Remorgida V, Anserini P. Influence of age on response to controlled ovarian stimulation in women with low levels of serum antiMüllerian hormone. Gynecol Endocrinol. 2020;3:1–5.
4. AydoganMathyk B, AslanÇetin B. Maternal serum anti-Müllerian hormone levels in pregnant women with gestational diabetes. Perinat J. 2018;26(2):74–7.
5. Gorkem TU, Togrul C. Is there a need to alter the timing of anti-müllerian hormone measurement during the menstrual cycle? Geburtshilfe Frauenheilkd. 2019;79:731–7.